Ligand Pharmaceuticals (LGND) Earning Somewhat Favorable News Coverage, Analysis Shows
Media stories about Ligand Pharmaceuticals (NASDAQ:LGND) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.8326828297376 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- 3 Reasons Why Ligand Pharmaceuticals (LGND) is a Great Momentum Stock (finance.yahoo.com)
- Insider Trading at Ligand Pharmaceuticals Incorporated? – ExpressNewsline (expressnewsline.com)
- Bruker Corporation (BRKR) is at $28.35 per share and Ligand Pharmaceuticals Incorporated (LGND) is listed at $124.05 – Stocks Gallery (stocksgallery.com)
- $29.36 Million in Sales Expected for Ligand Pharmaceuticals Incorporated (LGND) This Quarter (americanbankingnews.com)
- Jason Aryeh Sells 2,000 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock (americanbankingnews.com)
Several analysts have recently weighed in on the stock. TheStreet raised shares of Ligand Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Monday, August 7th. ValuEngine raised shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 10th. Stephens reissued an “overweight” rating and issued a $137.00 price target (up previously from $125.00) on shares of Ligand Pharmaceuticals in a research note on Wednesday, August 9th. BidaskClub raised shares of Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Finally, Roth Capital increased their price target on shares of Ligand Pharmaceuticals from $120.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, August 8th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Ligand Pharmaceuticals has an average rating of “Buy” and an average target price of $133.71.
Ligand Pharmaceuticals (NASDAQ:LGND) opened at 126.89 on Wednesday. Ligand Pharmaceuticals has a 52-week low of $87.50 and a 52-week high of $129.94. The stock has a market cap of $2.67 billion, a PE ratio of 309.49 and a beta of 0.96. The company’s 50 day moving average is $122.91 and its 200-day moving average is $113.41.
Ligand Pharmaceuticals (NASDAQ:LGND) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.42. The firm had revenue of $28 million for the quarter, compared to analyst estimates of $24.40 million. Ligand Pharmaceuticals had a net margin of 7.39% and a return on equity of 5.05%. The company’s revenue for the quarter was up 43.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.50 earnings per share. On average, equities analysts anticipate that Ligand Pharmaceuticals will post $2.95 earnings per share for the current year.
In related news, CEO John L. Higgins sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $114.87, for a total transaction of $1,378,440.00. Following the transaction, the chief executive officer now owns 151,171 shares of the company’s stock, valued at $17,365,012.77. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John L. Higgins sold 4,666 shares of the firm’s stock in a transaction that occurred on Wednesday, June 21st. The shares were sold at an average price of $120.00, for a total transaction of $559,920.00. Following the transaction, the chief executive officer now directly owns 143,837 shares in the company, valued at approximately $17,260,440. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,874 shares of company stock worth $6,022,156. Insiders own 14.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Ligand Pharmaceuticals (LGND) Earning Somewhat Favorable News Coverage, Analysis Shows” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/30/ligand-pharmaceuticals-lgnd-earning-somewhat-favorable-news-coverage-analysis-shows.html.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Stock Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.